Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737773 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAHPGDHIF1AHSD11B1 | |
| SCHEMBL15577442 | 0.92 | RAB9A (0.50) | ALDH1A1LMNAHPGDHSD11B1SLC18A3 | |
| SCHEMBL2027017 | 0.92 | RAB9A (0.50) | ALDH1A1LMNAHPGDHSD11B1SLC18A3 | |
| SCHEMBL14345495 | 0.86 | CASP6 (0.47) | ALDH1A1LMNAHPGDHIF1ASLC18A3 | |
| SCHEMBL3312540 | 0.85 | ALDH1A1 (0.62) | ALDH1A1LMNAHPGDHIF1AHSD11B1 | |
| SCHEMBL15513886 | 0.84 | SLC18A3 (0.42) | ALDH1A1HPGDSLC18A3POLBTSHR | |
| SCHEMBL23854774 | 0.84 | ALDH1A1 (0.50) | ALDH1A1LMNAHPGDHIF1AHSD11B1 | |
| SCHEMBL2552810 | 0.84 | ALDH1A1 (0.50) | ALDH1A1LMNAHPGDHIF1AHSD11B1 | |
| SCHEMBL9509660 | 0.84 | PROKR1 (0.60) | ALDH1A1LMNAHPGDHIF1APROKR1 | |
| SCHEMBL4099888 | 0.84 | RAB9A (0.57) | ALDH1A1LMNAHPGDHIF1AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084772-A | Nilapatinib intermediate, preparation method and method for preparing Nilapatinib by using same | 重庆博腾制药科技股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3668857-B1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-11629137-B2 | Methods of manufacturing of niraparib | TESARO, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3615513-B1 | METHODS OF MANUFACTURING OF NIRAPARIB | TESARO INC (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11161834-B2 | Methods of manufacturing of niraparib | TESARO, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | disclosed |
| US-10927095-B2 | Processes for the preparation of Niraparib and intermediates thereof | TEVA PHARMACEUTICALS INTERNATIONAL GMBH | 2021-02-23 | — | — | US | disclosed |
| EP-3668857-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2020-06-24 | — | — | EP | disclosed |
| US-20200190056-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2020-06-18 | — | — | US | disclosed |
| EP-2675793-A1 | FAK INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2013-12-25 | — | — | EP | disclosed |
| US-20130324532-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-12-05 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
| EP-2516392-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012110773-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2012-08-23 | — | — | WO | disclosed |
| WO-2011076678-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| CN-101932572-A | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | MERCK & CO INC | 2010-12-29 | — | — | CN | disclosed |
| EP-2240466-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | Merck Sharp & Dohme Limited (GB) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009087381-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LTD (GB) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | ALDH1A1 3192/4885LMNA 2556/4885HPGD 3082/4885 |
| US-10927095-B2 | Processes for the preparation of Niraparib and intermediates thereof | PARP1, PARP2, PARP3 | ALDH1A1 440/4885LMNA 1356/4885HPGD 853/4885 |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | ALDH1A1 440/4885LMNA 3001/4885HPGD 4397/4885 |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | ALDH1A1 440/4885LMNA 3001/4885HPGD 4397/4885 |
| US-11161834-B2 | Methods of manufacturing of niraparib | PARP2, PARP1, PARP3 | ALDH1A1 622/4885LMNA 2318/4885HPGD 958/4885 |
| US-11629137-B2 | Methods of manufacturing of niraparib | PARP2, PARP1, PARP3 | ALDH1A1 622/4885LMNA 2318/4885HPGD 958/4885 |
| US-20130324532-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | ALDH1A1 3192/4885LMNA 2556/4885HPGD 3082/4885 |
| US-20200190056-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | PARP1, PARP2, PARP3 | ALDH1A1 440/4885LMNA 1356/4885HPGD 853/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | ALDH1A1 440/4885LMNA 3001/4885HPGD 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.